October 18, 2024

Startup immuneAdvice wins Young Scientists Pitch Competition

Startup immuneAdvice wins Young Scientists Pitch Competition
Go back

Success for the NMI spin-off immuneAdvice: the startup took first place in the Young Scientists Pitch Competition at the bioRN Annual Conference on Wednesday, October 9, 2024. Dr. Björn Tränkle, one of the founders, presented the business idea.

The vision of immuneAdvice is the early response monitoring and control of immunotherapies with the so-called ICE-T technology. This new form of diagnostics is intended to enable individually tailored therapies and thus take personalized medicine one step forward.

Congratulations to the immuneAdvice team for this fantastic award!

Original News

Our latest News

discover more
A single swab is sufficient: Study paves the way for simplified tuberculosis diagnosis

A single swab is sufficient: Study paves the way for simplified tuberculosis diagnosis

Led by researchers from Heidelberg Faculty of Medicine at Heidelberg University and the University of California, San Francisco (USA), an international research team has evaluated a novel approach for the diagnosis of pulmonary tuberculosis. The method enables detection of Mycobacterium tuberculosis without laboratory infrastructure, within a markedly shorter time frame than conventional diagnostics, and using […]

read more
Hella Bühler Prize Awarded to DKFZ Researcher Angelika Feldmann

Hella Bühler Prize Awarded to DKFZ Researcher Angelika Feldmann

For her groundbreaking research on the regulation of gene activity, Angelika Feldmann has been awarded the 2026 Hella Bühler Prize, which comes with a grant of €100,000. Presented by Heidelberg University, the award is intended for young researchers in the Heidelberg research community who have already distinguished themselves through outstanding scientific achievements in cancer research. […]

read more
New Nature Publication by Akribion Therapeutics GmbH: RNA-triggered cell killing with CRISPR–Cas12a2

New Nature Publication by Akribion Therapeutics GmbH: RNA-triggered cell killing with CRISPR–Cas12a2

Scholz, P., Thompson, J., Crosby, K.T. et al. RNA-triggered cell killing with CRISPR–Cas12a2. Nature (2026). https://doi.org/10.1038/s41586-026-10466-y Abstract Selectively eradicating target cells on the basis of their genetic or transcriptional identity remains important in basic research, medicine, biotechnology and agriculture1,2,3. For applications involving bacteria, CRISPR nucleases offer promising options due to their ability to enact RNA-guided counterselection4,5,6,7; however, using these […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp